In Vivo Morphological Changes of Ciliary Body and Trabecular Meshwork in High Myopia Eyes With Open-angle Glaucoma in Their Accommodation Induced by Pilocarpine
Sponsor study identifier
interventional
120
0 countries
N/A
Study Start
May 1, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Glaucoma is the leading cause of irreversible blindness worldwide. Although the pathogenesis remains unclear, pathologic increase in intraocular pressure (IOP) due to blocked aqueous outflow through the trabecular-Schlemm canal is known to be an important risk factor, and reduction of IOP is the only clinically validated way to retard the progression of OAG. Ciliary muscle plays a central role in the trabecular meshwork-Schlemm canal outflow pathway. Clinical evidence suggests that ciliary muscle contraction stimulated by cholinergic receptor agonist and retraction of ciliary body position after cataract surgery can dilate the lumen of Schlemm canal and reduce IOP. Currently, Ultrasound biomicroscopy (UBM) can obtain two-dimensional images of the anterior segment using high-frequency Ultrasound transducers in medical imaging studies of the ciliary body - trabecular meshwork -Schlemm canal complex. UBM has better tissue penetration than Optical coherence tomography (OCT) and can image the ciliary body better, but it has a lower resolution (30um to 50um) and is poor at imaging tiny tissues such as trabecular meshwork and Schlemm canal. The latest swept-source OCT (SS-OCT) has faster image capture rate (1000000 A scans/SEC), stronger penetration and higher resolution (8um axial resolution and 20um transverse resolution). The structure and morphology of ciliary body-trabecular meshwork-Schlemm canal complex can be clearly photographed. The investigators intend to use CASIA2 to image the ciliary body-trabecular meshwork-Schlemm canal complex before and after administration of pilocarpine in healthy individuals and patients with glaucoma to assess the effect of pilocarpine on the anatomy of the ciliary body-trabecular meshwork-Schlemm canal complex.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 17, 2022
Actual (reported)April 29, 2022
Actual (reported)May 1, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Morphology of ciliary body
measurement of Morphology of ciliary body using CAISA2(The novel anterior segment optical coherence tomography (AS-OCT) device) and Image J software
baseline, pre-intervention(local application of pilocarpine eye drops)
Morphology of ciliary body
measurement of Morphology of ciliary body using CAISA2(The novel anterior segment optical coherence tomography (AS-OCT) device) and Image J software
40 minutes after the intervention(local application of pilocarpine eye drops)
Morphology of trabecular meshwork
measurement of Morphology of trabecular meshwork using CAISA2(The novel anterior segment optical coherence tomography (AS-OCT) device) and Image J software
baseline, pre-intervention(local application of pilocarpine eye drops)
Morphology of trabecular meshwork
measurement of Morphology of trabecular meshwork using CAISA2(The novel anterior segment optical coherence tomography (AS-OCT) device) and Image J software
40 minutes after the intervention(local application of pilocarpine eye drops)
emmetropia/low myopia (equivalent spherical lens \> -3.00d, astigmatism ≤ 1.5d), best corrected visual acuity ≥1.0
Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm
emmetropia/low myopia (equivalent spherical lens \> -3.00d, astigmatism ≤ 1.5d), diagnosed as POAG
Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
Yune Zhao
Ophthalmology and Optometry Hospital
Yune Zhao, MD
CONTACT
First Submitted
April 17, 2022
First Posted
April 29, 2022
Study Start
May 1, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm,diagnosed as POAG
Contact the study team to confirm eligibility.
June 2022
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 29, 2022
Record last verified: 2022-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: